Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
We assessed the preclinical characteristics of a novel, stringently screened selective estrogen receptor modulator, bazedoxifene acetate, including its ability to bind to and activate estrogen receptors and promote increased bone mineral density and bone strength in rats, and the effects impacting the uterine endometrium, breast cancer cell proliferation, and central nervous system-associated vasomotor responses in an animal model. Bazedoxifene bound to estrogen receptor-alpha with an IC50 of 26 nm, an affinity similar to that of raloxifene. Bazedoxifene did not stimulate proliferation of MCF-7 cells but did inhibit 17beta-estradiol-induced proliferation with an IC50 of 0.19 nm. In an immature rat uterine model, bazedoxifene (0.5 and 5.0 mg/kg) was associated with less increase in uterine wet weight than either ethinyl estradiol (10 microg/kg) or raloxifene (0.5 and 5.0 mg/kg). Histological analysis revealed that coadministration of bazedoxifene also appeared to reduce raloxifene-stimulated endometrial luminal epithelial cell and myometrial cell hypertrophy. In ovariectomized rats, bazedoxifene was associated with significant increases in bone mineral density at 6 wk, compared with control, and better compressive strength of bone samples from the L4 vertebrae, compared with samples from ovariectomized animals. In the morphine-addicted rat model of vasomotor activity, bone-sparing doses of bazedoxifene alone were not associated with 17beta-estradiol inhibition of increased vasomotor activity. Bazedoxifene acetate represents a promising new treatment for osteoporosis, with a potential for less uterine and vasomotor effects than selective estrogen receptor modulators currently used in clinical practice. Controlled clinical trial data will be needed to confirm these effects.
Komm
Barry S
BS
Wyeth Research, Women's Health Research Institute, Collegeville, Pennsylvania 19426, USA. kommb@wyeth.com
Kharode
Yogendra P
YP
Bodine
Peter V N
PV
Harris
Heather A
HA
Miller
Chris P
CP
Lyttle
C Richard
CR
D000818:Animals; D001833:Body Temperature Regulation / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology; D001943:Breast Neoplasms; D016466:CHO Cells; D006528:Carcinoma, Hepatocellular; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D019245:Compressive Strength; D006224:Cricetinae; D004717:Endometrium / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000378:metabolism*; D004967:Estrogens / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D008024:Ligands; D008055:Lipids / Q000097:blood; D008113:Liver Neoplasms; D009474:Neurons / Q000166:cytology; D010006:Osteoblasts / Q000166:cytology; D051381:Rats; D017207:Rats, Sprague-Dawley
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D004967:Estrogens; D007211:Indoles; D008024:Ligands; D008055:Lipids; C447119:bazedoxifene